Why did ABVX surge?

The surge of ABVX can be attributed to **Positive Phase 3 Clinical Trial Results**. 1. **ABVX's Announcement of Positive Phase 3 Trial Results**: Abivax SA (EPA:ABVX) (NASDAQ:ABVX) experienced an extraordinary surge in premarket trading on July 23, 2025, with shares skyrocketing over 400% following the announcement of positive Phase 3 clinical trial results for its ulcerative colitis treatment. The company reported compelling results from its ABTECT trials, which evaluated obefazimod, a first-in-class oral miR-124 enhancer, in patients with moderate to severely active ulcerative colitis. Little-Known French Biotech Firm’s US-Listed Shares Skyrocket in Premarket ABVX shares opened the premarket session at $49.88, representing a staggering 398.80% increase from the previous close of $10.00. The dramatic surge was triggered by the company’s announcement of successful Phase 3 trial results released after market hours on July 22, 2025. Trading volume spiked significantly as investors reacted to the breakthrough clinical data. (Source: ) 2. **Breakthrough Clinical Results**: The dramatic stock surge was driven by Abivax’s announcement of positive topline results from both ABTECT-1 and ABTECT-2 Phase 3 trials, which collectively enrolled 1,275 patients across over 600 clinical sites in 36 countries. Contingent on positive maintenance results, Abivax plans to submit New Drug Applications to both the FDA and European Medicines Agency in the second half of 2026, positioning obefazimod as a potential first-in-class treatment option for ulcerative colitis patients. (Source: ) 3. **Analyst Ratings and Price Targets**: Following the positive results, several analysts adjusted their ratings and price targets for Abivax. For example, Morgan Stanley upgraded Abivax from Equalweight to Overweight and raised its price target to $71.00 from $12.00. This reflects the optimism surrounding the drug's potential success and the market's confidence in Abivax's future. (Source: ) In summary, ABVX's surge is primarily driven by the announcement of positive Phase 3 clinical trial results for its ulcerative colitis treatment. This breakthrough led to a significant increase in the stock price, supported by positive analyst ratings and adjustments in price targets.